Sequence of therapies used in the model listed by initial therapy
| Therapy . | Ibrutinib . | Comparator . |
|---|---|---|
| Second line | Idelalisib + rituximab49 | Ibrutinib4 |
| Third line | Ofatumumab4 | Idelalisib + rituximab49 |
| Fourth line | Rituximab49 | Ofatumumab4 |
| Fifth line | Repeat of ofatumumab4 | Rituximab49 |
| Therapy . | Ibrutinib . | Comparator . |
|---|---|---|
| Second line | Idelalisib + rituximab49 | Ibrutinib4 |
| Third line | Ofatumumab4 | Idelalisib + rituximab49 |
| Fourth line | Rituximab49 | Ofatumumab4 |
| Fifth line | Repeat of ofatumumab4 | Rituximab49 |
The references in the table refer to the trials from which data regarding the progression probabilities while on therapy for relapsed disease were derived.